Drugs / TRASTUZUMAB ENVEDOTIN
Trials 9
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-02-06 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT-THE GROUP'S GASTRIC CANCER DRUG "DP303c" WAS GRANTED ORPHAN-DRUG DESIGNATION BY THE U.S. FDA irasia.com ↗
THE GROUP’S GASTRIC CANCER DRUG “DP303c” WAS GRANTED ORPHAN-DRUG DESIGNATION BY THE U.S. FDA |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-17 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION FOR TRASTUZUMAB ENVEDOTIN INJECTION ACCEPTED BY THE NMPA irasia.com ↗ |
| 2018-02-06 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT-THE GROUP'S GASTRIC CANCER DRUG "DP303c" WAS GRANTED ORPHAN-DRUG DESIGNATION BY THE U.S. FDA irasia.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRASTUZUMAB ENVEDOTIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068184 ↗ |
| Known as | DP303c | “First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors.” PMID 39266619 ↗ Sep 2024 |
| Known as | Trastuzumab envedotina | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068184 ↗ |
| Known as | Trastuzumab envedotine | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068184 ↗ |
| Modality | Monoclonal antibody | “one anti-HER2 monoclonal antibody” NCT06577376 ↗ |
| Route | Intravenous | “DP303c was administered intravenously every 3 weeks” PMID 39266619 ↗ Sep 2024 |
| Target | ERBB2 | “DP303c is a HER2-targeted ADC with a cleavable linker-MMAE payload.” PMID 39266619 ↗ Sep 2024 |